» Articles » PMID: 32606444

Benefit of Diverse Surgical Approach on Short-term Outcomes of MEN1-related Hyperparathyroidism

Overview
Journal Sci Rep
Specialty Science
Date 2020 Jul 2
PMID 32606444
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Surgical excision is the preferred treatment for multiple endocrine neoplasia type 1 (MEN1)-related primary hyperparathyroidism (PHPT), although controversy regarding the surgical strategy exists. We retrospectively investigated the short-term outcomes of PHPT by various surgical extents. Thirty-three patients who underwent parathyroidectomy due to MEN1-related PHPT at Yonsei Severance Hospital between 2005 and 2018 were included (age [mean ± SD], 43.4 ± 14.1 [range, 23-81] years). Total parathyroidectomy with auto-transplantation to the forearm (TPX) was the most common surgical method (17/33), followed by less-than-subtotal parathyroidectomy (LPX; 12/33) and subtotal parathyroidectomy (SPX; 4/33). There was no postoperative persistent hyperparathyroidism. Recurrence was high in the LPX group without significance (1 in TPX, 2 in SPX, and 3 in LPX, p = 0.076). Permanent and transient hypoparathyroidism were more common in TPX (n = 6/17, 35.3%, p = 0.031; n = 4/17, 23.5%, p = 0.154, respectively). Parathyroid venous sampling (PVS) was introduced in 2013 for preoperative localisation of hyperparathyroidism at our hospital; nine among 19 patients operated on after 2013 underwent pre-parathyroidectomy PVS, with various surgical extents, and no permanent hypoparathyroidism (p = 0.033) or post-LPX recurrence was observed. Although TPX with auto-transplantation is the standard surgery for MEN1-related PHPT, surgical extent individualisation is necessary, given the postoperative hypoparathyroidism rate of TPX and feasibility of PVS.

Citing Articles

Performance of [F]fluorocholine PET/CT in MEN1-related primary hyperparathyroidism before initial surgery or for persistent/recurrent disease.

Boucher A, Delabie J, Lussey-Lepoutre C, Haissaguerre M, Ouvrard E, Lavinia V Eur J Nucl Med Mol Imaging. 2023; 51(5):1349-1360.

PMID: 38057652 DOI: 10.1007/s00259-023-06537-1.


Ultrasound-guided microwave ablation in the treatment of recurrent primary hyperparathyroidism in a patient with MEN1: a case report.

Liu Z, Zhao Y, Han X, Hu X, Zhang Y, Xu L Front Endocrinol (Lausanne). 2023; 14:1175377.

PMID: 37795364 PMC: 10546301. DOI: 10.3389/fendo.2023.1175377.


Multiple endocrine neoplasia type 4 (MEN4): a thorough update on the latest and least known men syndrome.

Ruggeri R, Benevento E, De Cicco F, Grossrubatscher E, Hasballa I, Tarsitano M Endocrine. 2023; 82(3):480-490.

PMID: 37632635 DOI: 10.1007/s12020-023-03497-2.


Compound Heterozygous Variants of the Gene Co-Segregating in Two Chinese Pedigrees With Pigment Dispersion Syndrome/Pigmentary Glaucoma.

Tan J, Zeng L, Wang Y, Liu G, Huang L, Chen D Front Genet. 2022; 13:845081.

PMID: 35957697 PMC: 9358689. DOI: 10.3389/fgene.2022.845081.


Less Than Subtotal Parathyroidectomy for Multiple Endocrine Neoplasia Type 1 Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis.

Bouriez D, Gronnier C, Haissaguerre M, Tabarin A, Najah H World J Surg. 2022; 46(11):2666-2675.

PMID: 35767091 DOI: 10.1007/s00268-022-06633-7.


References
1.
Thakker R, Newey P, Walls G, Bilezikian J, Dralle H, Ebeling P . Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012; 97(9):2990-3011. DOI: 10.1210/jc.2012-1230. View

2.
Carling T . Multiple endocrine neoplasia syndrome: genetic basis for clinical management. Curr Opin Oncol. 2004; 17(1):7-12. DOI: 10.1097/01.cco.0000148567.29850.31. View

3.
Versnick M, Popadich A, Sidhu S, Sywak M, Robinson B, Delbridge L . Minimally invasive parathyroidectomy provides a conservative surgical option for multiple endocrine neoplasia type 1-primary hyperparathyroidism. Surgery. 2013; 154(1):101-5. DOI: 10.1016/j.surg.2013.03.004. View

4.
Kluijfhout W, Beninato T, Drake F, Vriens M, Gosnell J, Shen W . Unilateral Clearance for Primary Hyperparathyroidism in Selected Patients with Multiple Endocrine Neoplasia Type 1. World J Surg. 2016; 40(12):2964-2969. PMC: 5104782. DOI: 10.1007/s00268-016-3624-9. View

5.
Ginsburg M, Christoforidis G, Zivin S, Obara P, Wroblewski K, Angelos P . Adenoma localization for recurrent or persistent primary hyperparathyroidism using dynamic four-dimensional CT and venous sampling. J Vasc Interv Radiol. 2014; 26(1):79-86. DOI: 10.1016/j.jvir.2014.09.019. View